Exelixis to Present at the Deutsche Bank 42nd Annual Health Care Conference on May 3
April 24 2017 - 4:05PM
Business Wire
-- Presentation to be webcast on
www.exelixis.com --
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at Deutsche Bank’s
Health Care Conference taking place May 3-4 in Boston, MA. The
Exelixis presentation is scheduled for 11:20 AM EDT / 8:20 AM PDT
on Wednesday, May 3, 2017.
The presentation will be webcast live and may be accessed via
the Event Calendar page under Investors & Media at
www.exelixis.com. Please connect to the company’s website at least
15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the
webcast. A replay will also be available at the same location for
14 days.
About Exelixis
Exelixis, Inc. (Nasdaq: EXEL) is a biopharmaceutical company
committed to the discovery, development and commercialization of
new medicines to improve care and outcomes for people with cancer.
Since its founding in 1994, three products discovered at Exelixis
have progressed through clinical development, received regulatory
approval, and entered the marketplace. Two are derived from
cabozantinib, an inhibitor of multiple tyrosine kinases including
MET, AXL and VEGF receptors: CABOMETYX™ tablets approved for
previously treated advanced kidney cancer and COMETRIQ® capsules
approved for progressive, metastatic medullary thyroid cancer. The
third product, COTELLIC®, is a formulation of cobimetinib, a
selective inhibitor of MEK, is marketed under a collaboration with
Genentech (a member of the Roche Group), and is approved as part of
a combination regimen to treat advanced melanoma. Both cabozantinib
and cobimetinib have shown potential in a variety of forms of
cancer and are the subjects of broad clinical development programs.
For more information on Exelixis, please visit www.exelixis.com or
follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, COMETRIQ and
COTELLIC are registered U.S. trademarks, and CABOMETYX is a U.S.
trademark.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170424006420/en/
Exelixis, Inc.Susan Hubbard, 650-837-8194Executive Vice
President, Public Affairs and Investor
Relationsshubbard@exelixis.comorFor Exelixis, Inc.Hal Mackins,
415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Sep 2023 to Sep 2024